Latest From Alkermes PLC
Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.
Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.
The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.
- Large Molecule
- Nanotechnology, Chips, etc.
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alkermes Inc.
- Western Europe
- Parent & Subsidiaries
- Alkermes PLC
- Senior Management
Richard F Pops, Chmn. & CEO
James M Frates, SVP, CFO
Michael J Landine, SVP, Corp. Dev.
Craig Hopkinson, MD, CMO & SVP, Medicines Dev. & Medical Affairs
Georgianna Harris, PhD, SVP, Reg. Affairs
- Contact Info
Phone: 1 772 8000
1 Burlington Rd.
Dublin 4, MA D04 C5Y6
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.